AstraZeneca: Investing in Sustainable Mobility through E-Mobility

BUSINESS: 405 PRACTICES
At AstraZeneca, to respond effectively to a changing world and increased disease burden, we continuously invest in one of the most powerful and efficient production lines in the pharmaceutical industry. We work hard to deliver life-changing medicines and treatments to patients around the world.
We continue to push the boundaries of science to deliver innovative medicines and therapies that prevent, treat and cure some of the world's most important health challenges, including cancer, diabetes, heart, kidney and respiratory diseases. At AstraZeneca, innovation is a concept intertwined with growth. It is the driving force behind our vision to improve the lives of thousands of people by bringing them innovative treatments. At the same time, we ensure that these medicines reach the patients who need them, in a way that benefits society and our planet.
Reduce CO₂ emissions, enhance sustainable mobility, invest in infrastructure, and support employees’ green commuting.
Employees, business and medical community, general public.
2022–2023, ongoing.
AstraZeneca Greece completed the full transition of its fleet to electric vehicles, replacing 230 cars with zero-emission EVs. 42 chargers were installed at headquarters in Marousi and 100 home chargers were provided for employees. Selected chargers were 22kW with WiFi reporting, with costs of €1,800 + VAT per installation covered by the company. Preferential pricing was secured for other charger models.
The investment is part of Ambition Zero Carbon and the “Protecting the Environment… with Actions” program.
Greece – Headquarters (Marousi) & employees’ households.
Partnership with charging infrastructure suppliers and communication agencies.
All employees participated through EV adoption and home charger installations.